Research Topics
Species | N MattssonSummaryCountry: Sweden Publications
| Collaborators
|
Detail Information
Publications
Biochemical markers in Alzheimer's disease clinical trialsHenrik Zetterberg
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
Biomark Med 4:91-8. 2010....
CSF biomarker variability in the Alzheimer's Association quality control programNiklas Mattsson
Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden San Francisco VA Medical Center, Center for Imaging of Neurodegenerative Diseases, University of California San Francisco, San Francisco, CA, USA Electronic address
Alzheimers Dement 9:251-61. 2013..However, there are large variations in biomarker measurements among and within laboratories...- Amyloid-β metabolism in Niemann-Pick C disease models and patientsNiklas Mattsson
Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Molndal, Gothenburg, Sweden
Metab Brain Dis 27:573-85. 2012..The preliminary findings from NPC cats suggest that treatment with cyclodextrin may have an impact on APP processing pathways. CSF Aβ, sAPP and tau biomarkers were dynamically altered over time in human NPC patients... - Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42Niklas Mattsson
Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
Biomark Med 6:409-17. 2012..We describe possible technical approaches, focusing on a selected reaction monitoring mass spectrometry assay as a candidate reference method for quantification of CSF amyloid β42... - Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkersNiklas Mattsson
Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
Biomark Med 6:401-7. 2012..Global proficiency testing for CSF biomarkers is now fully established. It will continue to play an important part in the standardization of measurements that is a prerequisite for the broad-scale future implementation of CSF biomarkers... - Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairmentNiklas Mattsson
Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
J Alzheimers Dis 30:767-78. 2012..Knowledge on these biomarkers and their trajectories may facilitate early diagnosis of AD and be useful in future clinical trials to track effects of disease modifying drugs... 
BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous systemNiklas Mattsson
Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
PLoS ONE 7:e31084. 2012..The described CSF Aβ pattern may be used as a pharmacodynamic fingerprint to detect biochemical effects of BACE1-therapies in clinical trials, which might accelerate development of novel therapies...- Age and diagnostic performance of Alzheimer disease CSF biomarkersN Mattsson
Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, the Sahlgrenska Academy at University of Gothenburg, Mo lndal, Sweden
Neurology 78:468-76. 2012..These biomarkers identify AD already at the predementia stage, but their diagnostic performance might be affected by age-dependent increase of AD-type brain pathology in cognitively unaffected elderly... - Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer diseaseHenrik Zetterberg
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, S 431 80 Molndal, Sweden
Alzheimers Res Ther 2:32. 2010..Such biomarkers may be called 'theragnostic'. Here, we review the literature addressing the prospective value of these biomarkers... - Converging molecular pathways in human neural development and degenerationNiklas Mattsson
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at University of Gothenburg, Göteborg Mölndal, Sweden
Neurosci Res 66:330-2. 2010..Tau phosphorylation in Alzheimer's disease may be a physiological response to Alzheimer-associated synaptotoxicity... - Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosisNiklas Mattsson
Department of Neurochemistry and Psychiatry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Goteborg University, Molndal, Sweden
J Neurochem 103:1932-9. 2007..Further studies will investigate the involvement of these peptides in MS pathogenesis... - Reduced cerebrospinal fluid BACE1 activity in multiple sclerosisN Mattsson
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
Mult Scler 15:448-54. 2009..Cell and animal experiments have shown that beta-site APP-cleaving enzyme 1 (BACE1) may be involved in myelination... - Future screening for incipient Alzheimer's disease--the influence of prevalence on test performanceNiklas Mattsson
Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
Eur Neurol 62:200-3. 2009..A number of tentative solutions to the problem, apart from better tests, are discussed... - CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairmentNiklas Mattsson
Institute of Neuroscience and Physiology, Department of Neurochemistry and Psychiatry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
JAMA 302:385-93. 2009.... - The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkersNiklas Mattsson
Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
Alzheimers Dement 7:386-395.e6. 2011..In this article, we present the results from the first two rounds of the program... - Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utilityNiklas Mattsson
Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, S 431 80 Molndal, Sweden
Neuromolecular Med 13:151-9. 2011..Microglial markers are unlikely to be useful for AD diagnosis, but might be useful for identification of distinct subgroups of patients, and for the development and implementation of drugs targeting microglial pathology... - Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementiaNiklas Mattsson
Clinical Neurochemistry Laboratory, Sahlgren s University Hospital Mölndal, S 431 80 Molndal, Sweden
Mol Med Report 1:757-61. 2008..Taken together, these data suggest that differentially-expressed peptides are general markers of axonal degeneration. Further studies are needed to verify their prognostic value in FTD... - CSF biomarkers in neurodegenerative diseasesNiklas Mattsson
Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Molndal, Sweden
Clin Chem Lab Med 49:345-52. 2011..This article reviews the definitions, usage and current limitations of CSF biomarkers in this field... - Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional studyN Mattsson
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
Neurology 76:366-72. 2011..Our aim was to assess the effect of altered lipid constituents in neuronal membranes on amyloidogenic APP processing in humans... - Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fallNiklas Mattsson
Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Institute of Neuroscience and Physiology, Göteborg and Mölndal, Sweden
Clin Chem Lab Med 48:603-7. 2010..Here, we discuss the causes of these variations, and present a global quality control program to overcome them... - Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolismNiklas Mattsson
Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden
BMC Neurol 10:51. 2010..We have previously found altered cerebral amyloid metabolism in other neuroinflammatory conditions. To further elucidate this, we investigated amyloid metabolism in patients with Lyme neuroborreliosis (LNB)... - Converging pathways of chromogranin and amyloid metabolism in the brainNiklas Mattsson
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Gothenburg and Mölndal, Sweden
J Alzheimers Dis 20:1039-49. 2010..Cell medium from BACE1-inhibited cells had decreased CgB levels. These results suggest that a large part of AbetaPP in the human central nervous system is processed in the regulated secretory pathway of neurons... - Elevated cerebrospinal fluid levels of prostaglandin E2 and 15-(S)-hydroxyeicosatetraenoic acid in multiple sclerosisN Mattsson
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
J Intern Med 265:459-64. 2009.... - Intra-individual stability of CSF biomarkers for Alzheimer's disease over two yearsHenrik Zetterberg
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at Goteborg University, Molndal, Sweden
J Alzheimers Dis 12:255-60. 2007..Thus, even minor biochemical changes induced by treatment against AD should be detectable using these biomarkers, which bodes well for their usefulness as surrogate markers for drug efficacy in clinical trials... - CSF biomarkers: pinpointing Alzheimer pathogenesisNiklas Mattsson
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, S 431 80 Molndal, Sweden
Ann N Y Acad Sci 1180:28-35. 2009..Here, we review available CSF biomarkers for these pathological processes. We also consider their usability in clinical practice and in clinical trials... - Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patientsNiklas Mattsson
Clinical Neurochemistry Laboratory, Department of Neuroscience and Physiology, Sahlgren s University Hospital, S 431 80 Molndal, Sweden
Neurosci Lett 414:233-6. 2007..360, p=0.012). These results suggest that siblings of MS patients have an increased oxidative stress response to environmental and/or genetic factors that may be involved in MS pathogenesis...